DK3058371T3 - Anvendelse af acamprosat til at modulere erk-1-2-aktivering i dyremodeller til fxs og asd og individer diagnosticeret med fxs og asd - Google Patents
Anvendelse af acamprosat til at modulere erk-1-2-aktivering i dyremodeller til fxs og asd og individer diagnosticeret med fxs og asd Download PDFInfo
- Publication number
- DK3058371T3 DK3058371T3 DK14854852.2T DK14854852T DK3058371T3 DK 3058371 T3 DK3058371 T3 DK 3058371T3 DK 14854852 T DK14854852 T DK 14854852T DK 3058371 T3 DK3058371 T3 DK 3058371T3
- Authority
- DK
- Denmark
- Prior art keywords
- fxs
- asd
- acamprosate
- activation
- animal models
- Prior art date
Links
- AFCGFAGUEYAMAO-UHFFFAOYSA-N acamprosate Chemical compound CC(=O)NCCCS(O)(=O)=O AFCGFAGUEYAMAO-UHFFFAOYSA-N 0.000 title 1
- 229960004047 acamprosate Drugs 0.000 title 1
- 230000004913 activation Effects 0.000 title 1
- 238000010171 animal model Methods 0.000 title 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/48—Nerve growth factor [NGF]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N2333/91205—Phosphotransferases in general
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361890756P | 2013-10-14 | 2013-10-14 | |
| PCT/US2014/060527 WO2015057736A1 (en) | 2013-10-14 | 2014-10-14 | Use of acamprosate to modulate erk 1-2 activation in animal models for fxs and asd and individuals diagnosed with fxs and asd |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3058371T3 true DK3058371T3 (da) | 2021-08-02 |
Family
ID=52828619
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK14854852.2T DK3058371T3 (da) | 2013-10-14 | 2014-10-14 | Anvendelse af acamprosat til at modulere erk-1-2-aktivering i dyremodeller til fxs og asd og individer diagnosticeret med fxs og asd |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US10634677B2 (da) |
| EP (1) | EP3058371B1 (da) |
| JP (1) | JP6637414B2 (da) |
| AU (1) | AU2014337504B2 (da) |
| CA (1) | CA2926645C (da) |
| DK (1) | DK3058371T3 (da) |
| HU (1) | HUE056551T2 (da) |
| PL (1) | PL3058371T3 (da) |
| PT (1) | PT3058371T (da) |
| RU (1) | RU2696481C2 (da) |
| WO (1) | WO2015057736A1 (da) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3058371T3 (da) | 2013-10-14 | 2021-08-02 | Univ Indiana Res & Tech Corp | Anvendelse af acamprosat til at modulere erk-1-2-aktivering i dyremodeller til fxs og asd og individer diagnosticeret med fxs og asd |
| WO2017147044A1 (en) * | 2016-02-22 | 2017-08-31 | Indiana University Research And Technology Corporation | Peptides and methods for treatment of neurodegenerative diseases |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6316635B1 (en) | 1995-06-07 | 2001-11-13 | Sugen, Inc. | 2-indolinone derivatives as modulators of protein kinase activity |
| WO1997033585A1 (en) | 1996-03-11 | 1997-09-18 | Eli Lilly And Company | Method for treating autism |
| BR9911908A (pt) | 1998-07-06 | 2001-03-27 | Nsgene As | ácido nucléico, sequência de ácido nucléico, processos de usar um ácido nucléico, de usar o vetor, de fabricar o polipeptìdeo, de administrar o polipeptìdeo, de tratar uma doença ou distúrbio neurodegenerativos em um animal, de determinar se uma doença ou distúrbio neurodegenerativos em um animal, de produzir qualquer um polipeptìdeo, processo para identificar, isolar ou amplificar uma sequência de ácido nucléico de neublastina, de diagnosticar ou avaliar quanto a presença de uma doença ou distúrbio ou uma predisposiçãopara desnvolvê-los, para avaliar um polipeptìdeo de neublastina purificado ou um derivado ou fragmento deste ou um modulador da atividade dos precedentes quanto a atividade em tratar ou prevenir uma doença, de tratar um distúbio neurológico, de usar a sequência de um ou mais ácidos nucléicos, e para identificar um composto candidato que induza um efeito biológico mediado pela neuroblastina, vetor, célula transformada com ácido nucléico, polipeptìdeo, cmposição, anticorpo, gene sintético, e, conjunto. |
| US6593133B1 (en) | 1998-07-06 | 2003-07-15 | Nsgene A/S | Neurotrophic factors |
| US6610681B1 (en) | 1999-08-16 | 2003-08-26 | Revaax Pharmaceuticals, Llc | Neurotherapeutic clavulanate composition and method |
| SE0300586L (sv) | 2003-03-04 | 2004-09-05 | Forskarpatent I Syd Ab | Diagnos av autism |
| DK3305776T3 (da) | 2004-05-14 | 2019-12-09 | Vertex Pharma | Pyrrol-forbindelser som inhibitorer af erk-protein-kinaser og farmaceutiske sammensætninger, der indeholder disse forbindelser |
| US7595167B2 (en) | 2005-10-11 | 2009-09-29 | Blanchette Rockefeller Neurosciences Institute | Alzheimer's disease-specific alterations of the Erk1/Erk2 phosphorylation ratio |
| US20080139472A1 (en) | 2006-10-06 | 2008-06-12 | The Regents Of The University Of California | Upregulating bdnf levels to mitigate mental retardation |
| PL2083811T3 (pl) * | 2006-11-22 | 2017-05-31 | Clinical Research Associates, Llc | Sposoby leczenia zespołu downa, zespołu łamliwego chromosomu x oraz autyzmu |
| BRPI0719459A2 (pt) | 2006-12-22 | 2014-02-04 | Genentech Inc | "métodos para inibir a ligação do receptor de morte 6 (dr6) à proteína precursora amilóide (app), para o tratamento, para identificação de uma molécula de interesse que inibe a ligação do dr6 à app, para diagnosticar um paciente com, antagonista dr6 isolado, composição farmacêutica, artigo manufaturado e kit" |
| WO2008112772A2 (en) | 2007-03-14 | 2008-09-18 | Baylor Research Institute | Gene expression in peripheral blood mononuclear cells from children with diabetes |
| US20090082464A1 (en) | 2007-09-07 | 2009-03-26 | Bernd Jandeleit | Externally masked neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use |
| US20090239888A1 (en) * | 2008-02-12 | 2009-09-24 | Wisconsin Alumni Research Foundation | Methods for Inhibiting Amyloid Precursor Protein and Beta-Amyloid Production and Accumulation |
| MX2011000545A (es) * | 2008-07-14 | 2011-02-24 | Otonomy Inc | Composiciones de liberacion controlada para la modulacion de apoptosis y metodos para el tratamiento de trastornos oticos. |
| AU2010213683B2 (en) | 2009-02-12 | 2016-04-21 | Indiana University Research & Technology Corporation | Material and methods for treating developmental disorders including comorbid and idiopathic autism |
| US8008539B1 (en) | 2009-03-19 | 2011-08-30 | University Of South Florida | Generation of transgenic human soluble amyloid precursor protein alpha expressing mice |
| US20130052644A1 (en) | 2010-04-30 | 2013-02-28 | Baltazar Gomez-Mancilla | Predictive Markers Useful in the Treatment of Fragile X Syndrome (FXS) |
| US20110294879A1 (en) * | 2010-05-28 | 2011-12-01 | Xenoport, Inc. | Method of treatment of fragile x syndrome, down's syndrome, autism and related disorders |
| CA2808660A1 (en) | 2010-08-19 | 2012-02-23 | Blanchette Rockefeller Neurosciences Institute | Treatment of cognitive disorders associated with abnormal dendritic spines using pkc activators |
| RU2465273C2 (ru) | 2010-08-31 | 2012-10-27 | Общество С Ограниченной Ответственностью "Биофарм-Меморейн" | ГЕТЕРОЦИКЛИЧЕСКИЕ НИЗКОМОЛЕКУЛЯРНЫЕ sAPP-МИМЕТИКИ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СПОСОБЫ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ |
| AU2013293167B2 (en) | 2012-07-22 | 2019-04-18 | Indiana University Research And Technology Corporation | Modulation sAPP, sAPP alpha and BDNF levels in individuals diagnosed with FXS and ASD |
| DK3058371T3 (da) | 2013-10-14 | 2021-08-02 | Univ Indiana Res & Tech Corp | Anvendelse af acamprosat til at modulere erk-1-2-aktivering i dyremodeller til fxs og asd og individer diagnosticeret med fxs og asd |
-
2014
- 2014-10-14 DK DK14854852.2T patent/DK3058371T3/da active
- 2014-10-14 EP EP14854852.2A patent/EP3058371B1/en active Active
- 2014-10-14 PL PL14854852T patent/PL3058371T3/pl unknown
- 2014-10-14 CA CA2926645A patent/CA2926645C/en active Active
- 2014-10-14 AU AU2014337504A patent/AU2014337504B2/en active Active
- 2014-10-14 JP JP2016522755A patent/JP6637414B2/ja active Active
- 2014-10-14 WO PCT/US2014/060527 patent/WO2015057736A1/en not_active Ceased
- 2014-10-14 RU RU2016118551A patent/RU2696481C2/ru active
- 2014-10-14 US US15/029,596 patent/US10634677B2/en active Active
- 2014-10-14 PT PT148548522T patent/PT3058371T/pt unknown
- 2014-10-14 HU HUE14854852A patent/HUE056551T2/hu unknown
-
2020
- 2020-03-13 US US16/818,854 patent/US11733243B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20160266120A1 (en) | 2016-09-15 |
| RU2016118551A (ru) | 2017-11-21 |
| HUE056551T2 (hu) | 2022-02-28 |
| WO2015057736A1 (en) | 2015-04-23 |
| EP3058371B1 (en) | 2021-06-16 |
| US20200225233A1 (en) | 2020-07-16 |
| PL3058371T3 (pl) | 2021-11-08 |
| US11733243B2 (en) | 2023-08-22 |
| CA2926645C (en) | 2022-10-25 |
| AU2014337504B2 (en) | 2020-01-30 |
| EP3058371A4 (en) | 2017-04-19 |
| JP6637414B2 (ja) | 2020-01-29 |
| US10634677B2 (en) | 2020-04-28 |
| PT3058371T (pt) | 2021-07-26 |
| RU2016118551A3 (da) | 2018-07-24 |
| RU2696481C2 (ru) | 2019-08-02 |
| JP2016536293A (ja) | 2016-11-24 |
| CA2926645A1 (en) | 2015-04-23 |
| EP3058371A1 (en) | 2016-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL290613A (en) | Humanized or chimeric cd3 antibodies | |
| DK3071696T3 (da) | C/ebp alfa kort aktiverings-rna-sammensætninger og fremgangsmåder til anvendelse | |
| DK3086807T3 (da) | Antistoffer og fremgangsmåder til anvendelse | |
| IL242825B (en) | Systems and methods for diagnosis of depression and other medical conditions | |
| PL3613439T3 (pl) | Chimeryczny receptor antygenowy i sposoby jego zastosowania | |
| DK3736292T3 (da) | Anti-CD3-antistoffer og fremgangsmåder til anvendelse | |
| EP2948848A4 (en) | PARALLEL TRACKING FOR PERFORMANCE AND DETAIL | |
| KR102195650B9 (ko) | 통합된 폐쇄 장치 구성요소 및 방법 | |
| DK3079719T3 (da) | ANTI-SIGLEC-8-antistoffer og fremgangsmåder til anvendelse deraf | |
| PL3053071T3 (pl) | Metody i procesy nieinwazyjnej oceny zmienności genetycznych | |
| DK3022707T3 (da) | Systemer og fremgangsmåder til at monitorere bevægelse af sygdomsfelt | |
| DK2844672T3 (da) | Humane antistoffer over for Fel d1 og fremgangsmåder til anvendelse deraf | |
| EP3794941C0 (en) | ANIMAL MODELS AND THERAPEUTIC MOLECULES | |
| HRP20170840T1 (hr) | Supstituirani ksantini i metode njihove uporabe | |
| DK3090068T3 (da) | Fremgangsmåde og kit til ikke-invasiv detektering af egfr-genmutationer | |
| GEAP201814045A (en) | Methods for fixing hair and skin | |
| DK2964767T3 (da) | Toksingener og fremgangsmåder til anvendelse deraf | |
| IL244590A0 (en) | Anti-epcam antibodies and methods of use | |
| IL244200A0 (en) | Nsaid and sigma receptor ligand combinations | |
| EP3744284C0 (en) | HEAD AND JAW IMMOBILIZATION DEVICE | |
| BR112015002610A2 (pt) | modelo animal de obesidade e métodos de sua fabricação e uso | |
| IL246658B (en) | Systems and methods for diagnosing sleep | |
| DK3560937T3 (da) | Fremgangsmåder til fremstilling af 18f-mærkede psma-målrettede billeddannelsesmidler og diagnostiske fremgangsmåder dermed | |
| DK3029038T3 (da) | Tetrazolinonforbindelse og anvendelse deraf | |
| EP2989432C0 (en) | IMAGING APPARATUS AND METHOD |